Royalty Pharma PLC (RPRX)
27.39
-0.07
(-0.25%)
USD |
NASDAQ |
Jun 10, 16:00
27.40
+0.01
(+0.04%)
After-Hours: 20:00
Royalty Pharma Cash from Financing (Quarterly): -212.00M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -212.00M |
| December 31, 2023 | -231.89M |
| September 30, 2023 | -1.359B |
| June 30, 2023 | -347.00M |
| March 31, 2023 | -210.37M |
| December 31, 2022 | -265.55M |
| September 30, 2022 | -230.09M |
| June 30, 2022 | -228.25M |
| March 31, 2022 | -220.97M |
| December 31, 2021 | -198.07M |
| September 30, 2021 | 1.034B |
| Date | Value |
|---|---|
| June 30, 2021 | -224.42M |
| March 31, 2021 | -226.67M |
| December 31, 2020 | -277.39M |
| September 30, 2020 | -357.39M |
| June 30, 2020 | 1.579B |
| March 31, 2020 | 542.52M |
| December 31, 2019 | -285.80M |
| September 30, 2019 | -280.69M |
| June 30, 2019 | -310.18M |
| March 31, 2019 | -314.96M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.359B
Minimum
Sep 2023
1.579B
Maximum
Jun 2020
-115.50M
Average
-229.17M
Median
Cash from Financing (Quarterly) Benchmarks
| Cytokinetics Inc | 103.79M |
| Agios Pharmaceuticals Inc | 5.864M |
| Viatris Inc | -425.60M |
| Arrowhead Pharmaceuticals Inc | 430.78M |
| Insmed Inc | 3.022M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 664.64M |
| Cash from Investing (Quarterly) | -86.65M |
| Free Cash Flow | 2.619B |
| Free Cash Flow Per Share (Quarterly) | 1.112 |
| Free Cash Flow to Equity (Quarterly) | 660.55M |
| Free Cash Flow to Firm (Quarterly) | 701.45M |
| Free Cash Flow Yield | 15.92% |